PPARgamma agonist 19 (Compound 5e) is a PPARgamma agonist. PPARgamma agonist 19 has an IC50 of 11.27 µM against COX-1 and an IC50 of 0.05 µM against COX-1. PPARgamma agonist 19 increases glucose uptake in rat hemidiaphragm assay and is superior to pioglitazone (HY-13956). PPARgamma agonist 19 alleviates hyperglycemia and insulin resistance in an in vivo model of type 2 diabetes in rats and protects against renal and lipidemia damage caused by metabolic dysfunction[1].
Molekulargewicht:
503.57
Formel:
C20H17N5O5S3
Target-Kategorie:
COX,PPAR
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
